Discover and read the best of Twitter Threads about #Glioblastoma
Most recents (18)
$NWBO #DCVaxL
The #PolyICLC adjuvant has already been approved for adjuvant use in other cancers. Under new FDA rules, real world data and validation of the results already seen may make it very easy not only to expand the label and access to #Hiltonol, but also ease insurance / Medicare if
If #DCVaxL is approved. It should be straightforward to add #PolyICLC $NWBO.
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
A lot of people are starting to notice IMHO. $NWBO #DCVaxL
Phase 3 results: $NWBO #DCvaxL
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination w/Extension of Survival Among Patients w/[BOTH] #NewlyDiagnosed & #Recurrent #Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial #CancerVaccine
jamanetwork.com/journals/jamao…
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination w/Extension of Survival Among Patients w/[BOTH] #NewlyDiagnosed & #Recurrent #Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial #CancerVaccine
jamanetwork.com/journals/jamao…
Mind blowing interim, unpublished data #DCVaxL data from UCLA #DrLindaLiau presentation for use with adjuvant #PolyICLC #TLR3Agonist #Hiltonol #glioblastoma #cancervaccine
🚨Our new study is out @CellReports!
We use single cell protein quantification & single cell FISH to map #spatial interactions in genetic mosaicism & tumor microenvironment in #Glioblastoma!
Wonderful collaboration w/ @janiszewska_lab @DalitEngelhardt
@Kacper_W_PhD
Deep dive👇
We use single cell protein quantification & single cell FISH to map #spatial interactions in genetic mosaicism & tumor microenvironment in #Glioblastoma!
Wonderful collaboration w/ @janiszewska_lab @DalitEngelhardt
@Kacper_W_PhD
Deep dive👇
First, some context.
Glioblastoma (GBM) is one of the deadliest, most aggressive cancers that exist, with a median survival of only 15 months.
In GBM, 'single cell heterogeneity' are not simply buzzwords.
Rather, this immense heterogeneity is a main reason of treatment failure
Glioblastoma (GBM) is one of the deadliest, most aggressive cancers that exist, with a median survival of only 15 months.
In GBM, 'single cell heterogeneity' are not simply buzzwords.
Rather, this immense heterogeneity is a main reason of treatment failure
Recent work demonstrated that single GBM tumors are mosaics of cells in different states, each associated with distinct genomic driver alterations.
While transitions between cell states can occur, each genetic driver favors a particular cell state.
tinyurl.com/mrx2jpj8
While transitions between cell states can occur, each genetic driver favors a particular cell state.
tinyurl.com/mrx2jpj8
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy from 2011, #DCVaxL with #PolyICLC #Glioblastoma #GBM
aacrjournals.org/clincancerres/…
aacrjournals.org/clincancerres/…
#DCVaxL & #PolyICLC #TLR3Inhibitor as adjuvant, have been an impressive combination since 2011:
Results: DC vaccinations are safe and not associated with any dose-limiting toxicity.
Results: DC vaccinations are safe and not associated with any dose-limiting toxicity.
The median overall survival from the time of initial surgical diagnosis of glioblastoma was 31.4 months, with a 1-, 2-, and 3-year survival rate of 91%, 55%, and 47%, respectively.
[1/5] #Glioblastoma comprises 49.1% of all primary malignant brain tumors and approximately 12,000 cases are diagnosed each year in the US. A recent study In @JAMAOnc investigated whether the addition of an...
[2/5] autologous tumour lysate-loaded dendritic cell vaccine (DCVax-L) to the traditional standard of treatment (#surgery, #radiotherapy, and #chemotherapy) for glioblastoma prolonged survival.
#Neurology #Oncology #brain
#Neurology #Oncology #brain
[3/5] DCVax-L was found to be promising in extending survival for patients with newly diagnosed glioblastoma who are also receiving standard treatment for their disease.
#HealthcareNews #medicine #MedEd
#HealthcareNews #medicine #MedEd
‘I’m just carrying on’: vaccine gives brain cancer patient years of extra life
The revolutionary DCVax-L vaccine has allowed Nigel French to live a normal life seven years after a brain cancer diagnosis #DCVaxL $NWBO #CancerVaccine #Glioblastoma #Phase3
theguardian.com/science/2022/n…
The revolutionary DCVax-L vaccine has allowed Nigel French to live a normal life seven years after a brain cancer diagnosis #DCVaxL $NWBO #CancerVaccine #Glioblastoma #Phase3
theguardian.com/science/2022/n…
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma $NWBO #DCVaxL #CancerVaccine #GBM
A Phase 3 Prospective Externally Controlled Cohort Trial
jamanetwork.com/journals/jamao…
A Phase 3 Prospective Externally Controlled Cohort Trial
jamanetwork.com/journals/jamao…
More long-term Survivors, $NWBO #DCVaxL a personalized general therapeutic #CancerVaccine to treat any kind of solid tumor cancer anywhere in the body.
Cooling brain tumors. Prolonging (rodent) lives.
🧠🐭
Out in @ScienceAdvances:
science.org/doi/10.1126/sc…
@dukeengineering @utswnews @AKUGlobal
#glioblastoma #bioengineering #medicaldevices #cancer #brain
🧠🐭
Out in @ScienceAdvances:
science.org/doi/10.1126/sc…
@dukeengineering @utswnews @AKUGlobal
#glioblastoma #bioengineering #medicaldevices #cancer #brain
Question that hit me on October 26th, 2017: is there a temperature window that stops 🛑 tumor growth, and the brain 🧠 can tolerate? If so, this could prevent tumor recurrence and buy the patient time to try therapies until we reach a cure.
2/12
2/12
🔑findings:
1. Tumor cells stop growing at room temperature (20-25°C). Remember, body temperature is 37°C.
Even 18 hours of cooling per day can be enough! 🕒 This point will be useful for a device in the future.
3/12
1. Tumor cells stop growing at room temperature (20-25°C). Remember, body temperature is 37°C.
Even 18 hours of cooling per day can be enough! 🕒 This point will be useful for a device in the future.
3/12
Exploring Adjuvants with #DCVaxL: POLY ICLC TLR 3 Agonist adjuvant discussion, #DrLindaLiau, early trial P 1. Using adjuvants w/ #DCVaxL $NWBO #Murcidencel #DCVax
Survival Data w/Adjuvants, small early trial:
Survival Data w/Adjuvants, small early trial:
Fuller Discussion re early trial with #DCVaxL + adjuvants, including Poly ICLC:
Re single agent checkpoint inhibitors, without DCVaxL, in Glioblastoma:
$NWBO #DCVaxL New name #murcidencel
SNO Abstract, just released, for presentation by #DrLindaLiau on November 20th:
Background: Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years.
SNO Abstract, just released, for presentation by #DrLindaLiau on November 20th:
Background: Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years.
We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and
Methods: Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo.
Methods: Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo.
Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo.
Dr. Keyoumars Ashkan #DrKeyoumarsAshkan Surgeon & professor, and he also ran the European trials for #DCVaxL from $NWBO
Professor Ashkan performs life-saving awake brain tumour surgery while patient plays violin! via @YouTube
Some quick thoughts on $NWBO and #DCVaxL. DCVaxL is designated an #OrphanDrug, for an #OrphanDisease, #Glioblastoma. This provides a bunch of benefits which are off topic for this thread.
My main point is to suggest that patients needing #DCVaxL may likely qualify for either of two funds in the UK, the #InnovativeMedicinesFund or the #CancerDrugsFund, which together have £640M allocated to provide early coverage to patients in the UK's NHS.
The UK charity, BrainTumorResearch.org recently put out a PR about the new program in the UK for rare diseases, which is modeled on an already existing program called the #CancerDrugsFund.
1/ Re $NWBO and #DCVaxL aka "ATL-DC" in brief:
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
2/ $NWBO and UCLA have a patent application pending approval for immunotherapy combinations with #DCVaxL.
3/ The #DCVaxLComboTrial appears to be intended to further the patent process and also to likely advance new commercial opportunities, including potential partnerships, for $NWBO. Many commentators have suggested some obvious potential partners.
Un bellissimo studio da @Unibo avrebbe individuato un gene responsabile della produzione di un enzima fondamentale in molti processi cerebrali: la sua espressione sarebbe inversamente correlata al grado di malignità del #Glioblastoma. Un breve thread divulgativo. 1/n 🧵
Il glioblastoma è un tumore del sistema nervoso centrale caratterizzato da una popolazione eterogenea di cellule geneticamente instabili, con alta capacità infiltrativa, promotrici di angiogenesi e resistenti alle terapie oggi disponibili. 2/n
La prognosi, purtroppo, è molto sfavorevole, con una sopravvivenza mediana tra 12 e 14 mesi. Le terapie principali si basano su interventi neurochirurgici, chemioterapia e radioterapia: tecniche altamente invasive, che non offrono cure definitive. 3/n
Good morning. Not looking for sympathy. Sharing the truth hoping to raise awareness.
Please remember Glioblastoma multiforme is a grade IV brain tumour. I am Not in remission. There is No Cure. I still have piece of the glioma in my head.
This unique form of brain cancer and the survivorship is extremely grim. The Life expectancy is 12-16 months and the five-year survival rate is only 6.8 percent.
I get inspired by real world problems that I feel are solvable with data, because then it becomes within my scope to tackle. If I look at #glioblastoma I see room for #blockchain to provide clarity on #patientconsent for uses to enable monetization, ideally to help offset costs.
To unpack these things further, I mean leveraging smart contracts for dynamic consent or 'prosent' as presented here: jme.bmj.com/content/early/…
This would allow for the patient to opt into selling their data to researches, insurance or pharmaceutical companies
This would allow for the patient to opt into selling their data to researches, insurance or pharmaceutical companies
Another resource I've found is this one on how the Malta Biobank is using dynamic consent via hyperledger fabric...
"a more robust model could lay the foundation for a closer collaboration between biobank managers, researchers, and research partners" doi.org/10.1038/s41431…
"a more robust model could lay the foundation for a closer collaboration between biobank managers, researchers, and research partners" doi.org/10.1038/s41431…
Very pleased the Senate passed our resolution designating July 22, 2020 as #GlioblastomaAwarenessDay.
Glioblastoma is a devastating brain disease that has taken the lives of two of my very close friends and colleagues, Ted Kennedy and my dearest friend John McCain.
#GBMDay
Glioblastoma is a devastating brain disease that has taken the lives of two of my very close friends and colleagues, Ted Kennedy and my dearest friend John McCain.
#GBMDay
To honor their lives and the lives of those currently battling #Glioblastoma this resolution shines a light on this terrible disease and urges collaboration between brain tumor researchers so we can eradicate this cancer.
I want to thank @SenatorSinema @SenWarren @SenMcSallyAZ @SenMarkey for their efforts on passing this resolution.
We are committed to combating and defeating this terrible disease.
We are committed to combating and defeating this terrible disease.
More on immune evasion in glioblastoma! Online now in @NatureMedicine, intracranial tumors drive sequestration of T cells in the bone marrow through downregulation of S1PR1 receptor surface expression. nature.com/articles/s4159…
GBM patients, including treatment-naive, and mice with a variety of intracranial tumors (regardless of tumor origin) show extremely low levels of circulating T cells and reduced spleen size, with accompanying increase in bone marrow T cells (especially naive T cells).
This seems to be due to lower S1PR1 on T cells, driven by ligand-independent internalization (RNA levels are identical between control and tumor-bearing mice and there is no increase of S1P in the tumor-bearing mice).
Reading this review on immunotherapy in glioblastoma (nature.com/articles/s4157…) @NatRevClinOncol . A few odds and ends make me wonder - is there going to be a special role for NK cells in glioblastoma? Should we be aiming to target them for more effective therapies?
Checkpoint blockade hasn’t shown much efficacy in glioblastoma, in line with relatively low mutational burden (nejm.org/doi/full/10.10…) @NEJM. Also in line with the brain as “immunoprivileged”, or at least as a place with "unusual" immune activity.
First started thinking about NK cells in GBM after reading excellent study on PDGF-DD as an activating NK cell ligand (sciencedirect.com/science/articl…) @CellCellPress - striking human data from GBM cohorts, especially with greater infiltration of NK cells than T cells into tumor.
